Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Vaccine | Jan 17, 2012

BACKGROUND: DNA vaccines remain an important component of HIV vaccination strategies, typically as part of a prime/boost vaccination strategy with viral vector or protein boost. A number of DNA prime/viral vector boost vaccines are currently being evaluated for both preclinical studies and in Phase I and Phase II clinical trials. These vaccines would benefit from molecular adjuvants that increase correlates of immunity during the DNA prime. While HIV vaccine immune correlates are still not well defined, there are a number of immune assays that have been shown to correlate with protection from viral challenge including CD8+ T cell avidity, antigen-specific proliferation, and polyfunctional cytokine secretion. METHODOLOGY AND PRINCIPAL FINDINGS: Recombinant DNA vaccine adjuvants composed of a fusion between Surfactant Protein D (SP-D) and either CD40 Ligand (CD40L) or GITR Ligand (GITRL) were previously shown to enhance HIV-1 Gag DNA vaccines. Here we show that similar fusion constructs composed of the TNF superfamily ligands (TNFSFL) 4-1BBL, OX40L, RANKL, LIGHT, CD70, and BAFF can also enhanced immune responses to a HIV-1 Gag DNA vaccine. BALB/c mice were vaccinated intramuscularly with plasmids expressing secreted Gag and SP-D-TNFSFL fusions. Initially, mice were analyzed 2 weeks or 7 weeks following vaccination to evaluate the relative efficacy of each SP-D-TNFSFL construct. All SP-D-TNFSFL constructs enhanced at least one Gag-specific immune response compared to the parent vaccine. Importantly, the constructs SP-D-4-1BBL, SP-D-OX40L, and SP-D-LIGHT enhanced CD8+ T cell avidity and CD8+/CD4+ T cell proliferation 7 weeks post vaccination. These avidity and proliferation data suggest that 4-1BBL, OX40L, and LIGHT fusion constructs may be particularly effective as vaccine adjuvants. Constructs SP-D-OX40L, SP-D-LIGHT, and SP-D-BAFF enhanced Gag-specific IL-2 secretion in memory T cells, suggesting these adjuvants can increase the number of self-renewing Gag-specific CD8+ and/or CD4+ T cells. Finally adjuvants SP-D-OX40L and SP-D-CD70 increased T(H)1 (IgG2a) but not T(H)2 (IgG1) antibody responses in the vaccinated animals. Surprisingly, the B cell-activating protein BAFF did not enhance anti-Gag antibody responses when given as an SP-D fusion adjuvant, but nonetheless enhanced CD4+ and CD8+ T cell responses. CONCLUSIONS: We present evidence that various SP-D-TNFSFL fusion constructs can enhance immune responses following DNA vaccination with HIV-1 Gag expression plasmid. These data support the continued evaluation of SP-D-TNFSFL fusion proteins as molecular adjuvants for DNA and/or viral vector vaccines. Constructs of particular interest included SP-D-OX40L, SP-D-4-1BBL, SP-D-LIGHT, and SP-D-CD70. SP-D-BAFF was surprisingly effective at enhancing T cell responses, despite its inability to enhance anti-Gag antibody secretion.

Pubmed ID: 22146759 RIS Download

Mesh terms: AIDS Vaccines | Adjuvants, Immunologic | Animals | CD8-Positive T-Lymphocytes | Cell Proliferation | Female | HIV-1 | Humans | Injections, Intramuscular | Ligands | Mice | Mice, Inbred BALB C | Recombinant Fusion Proteins | Tumor Necrosis Factor-alpha | Vaccines, DNA | gag Gene Products, Human Immunodeficiency Virus

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, Id: 1R21AI63982
  • Agency: NIAID NIH HHS, Id: R21 AI063982
  • Agency: NIAID NIH HHS, Id: R21 AI078834-01
  • Agency: NIAID NIH HHS, Id: R21AI088511
  • Agency: NIAID NIH HHS, Id: R21 AI088511
  • Agency: NIAID NIH HHS, Id: 1R21AI073240
  • Agency: NIAID NIH HHS, Id: 1R21AI078834
  • Agency: NIAID NIH HHS, Id: R21 AI078834-02
  • Agency: NIAID NIH HHS, Id: K22 AI068489-02
  • Agency: NIAID NIH HHS, Id: P30 AI073961
  • Agency: NIAID NIH HHS, Id: R21 AI073240
  • Agency: NIAID NIH HHS, Id: K22 AI068489
  • Agency: NIAID NIH HHS, Id: R21 AI078834
  • Agency: NIAID NIH HHS, Id: P30 AI036214
  • Agency: NIAID NIH HHS, Id: K22 AI068489-01A2
  • Agency: NIAID NIH HHS, Id: 1K22AI068489
  • Agency: NIAID NIH HHS, Id: 1P30AI073961

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.